Key Events This Week
Apr 13: Upgrade to Hold rating as technicals and financials improve
Apr 15: Stock jumps 5.00% amid strong volume
Apr 16: Continued gains with 4.99% rise
Apr 17: Death Cross formation signals potential bearish trend

Checkpoint Trends Ltd Forms Death Cross Signalling Potential Bearish Trend
2026-04-17 18:00:15Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, raising concerns about the stock's medium to long-term momentum despite its recent volatile performance.
Read full news article
Checkpoint Trends Ltd Upgraded to Hold as Technicals and Financials Improve
2026-04-13 08:09:00Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 10 April 2026. This change reflects a combination of improved technical indicators, robust financial performance, attractive valuation metrics, and a positive quality assessment, signalling a cautious but optimistic outlook for investors.
Read full news article
Checkpoint Trends Ltd Downgraded to Sell Amid Mixed Technicals and Valuation Concerns
2026-04-07 08:18:26Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 6 April 2026. This shift reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals, highlighting both strengths and emerging concerns in the company’s outlook.
Read full news article
Checkpoint Trends Ltd Valuation Shifts to Very Attractive Amid Market Volatility
2026-03-04 08:00:34Checkpoint Trends Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by improved price-to-earnings and price-to-book value metrics. This change comes amid a challenging market backdrop where the stock has underperformed the Sensex in the short term but continues to deliver exceptional long-term returns, prompting a reassessment of its price attractiveness relative to peers in the Pharmaceuticals & Biotechnology sector.
Read full news article
Checkpoint Trends Ltd is Rated Hold by MarketsMOJO
2026-02-22 10:10:41Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Checkpoint Trends Ltd is Rated Hold by MarketsMOJO
2026-02-10 10:11:11Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Checkpoint Trends Ltd is Rated Hold
2026-01-30 10:10:35Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 04 September 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.
Read full news articleAre Checkpoint Trends Ltd latest results good or bad?
2026-01-29 19:20:20Checkpoint Trends Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth alongside notable profitability challenges. The company's net sales reached ₹174.09 crores, reflecting a sequential growth of 60.32% from the previous quarter, which is a substantial increase compared to the same period last year. This growth trajectory underscores the company's successful pivot from pharmaceutical manufacturing to trading operations, marking a remarkable year-on-year revenue increase of 173,990%. However, this revenue surge has not translated into improved profitability. The net profit for the quarter was ₹0.57 crores, representing a decline of 56.82% from the prior quarter's net profit of ₹1.32 crores. Additionally, the operating margin has contracted to 0.44%, down from 1.65% in Q2 FY26, indicating that the company is facing challenges in converting its sale...
Read full news article





